ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
Ianza, A, Giudici, F, Pinello, C, Corona, SP, Strina, C, Bernocchi, O, Bortul, M, Milani, M, Sirico, M, Allevi, G, Aguggini, S, Cocconi, A, Azzini, C, Dester, M, Cervoni, V, Bottini, A, Cappelletti, M, Generali, D
Published in Tumor biology (01.06.2020)
Published in Tumor biology (01.06.2020)
Get full text
Journal Article
227P Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
Vernieri, C., Zattarin, E., Mariani, L., Menichetti, A., Leporati, R., Ligorio, F., Fuca, G., Lobefaro, R., Griguolo, G., Sirico, M., Bernocchi, O., Marra, A., Agostinetto, E., Jacobs, F., di Mauro, P., Curigliano, G., Pedersini, R., Losurdo, A., Generali, D., Dieci, M.V.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: A retrospective exploratory analysis of the BALLET study
Corona, S., Giudici, F., Jerusalem, G., Ciruelos, E., Strina, C., Sirico, M., Bernocchi, O., Milani, M., Dester, M., Ziglioli, N., Barbieri, G., Cervoni, V., Montemurro, F., Generali, D.
Published in European journal of cancer (1990) (01.10.2020)
Published in European journal of cancer (1990) (01.10.2020)
Get full text
Journal Article
300P Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study
Zattarin, E., Fabbroni, C., Ligorio, F., Marra, A., Corti, C., Bernocchi, O., Sirico, M., Generali, D.G., Curigliano, G., Bianchi, G., Capri, G., Rivoltini, L., De Braud, F.G.M., Vernieri, C.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study
Nichetti, F., Marra, A., Giorgi, C.A., Randon, G., Scagnoli, S., De Angelis, C., Molinelli, C., Ferraro, E., Trapani, D., Milani, A., Agostinetto, E., Bernocchi, O., Catania, G., Rea, C.G., Basile, D., Gerratana, L., Cinausero, M., Vernieri, C.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article